HDAC9 and cancer: Despite favorable toxicity profiles and reversible adverse effects, HDAC inhibitors seem to be not sufficient as monotherapies in solid tumors compared with current standard cancer therapies, partly because of their poor pharmacokinetic properties [11, 91].